Redox-active metals, oxidative stress, and Alzheimer's disease pathology

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 153-163

  Huang, Xudong ^a   Moir, Robert D ^a   Tanzi, Rudolph E ^a   Bush, Ashley I ^a,b   Rogers, Jack T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Antioxidant; A amyloidosis; Metal cbelator; Metals; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; CHELATING AGENT; COPPER; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON; METAL DERIVATIVE; METALLOPROTEIN; REACTIVE OXYGEN METABOLITE; REDUCING AGENT;

ALZHEIMER DISEASE; BRAIN TISSUE; CADAVER; FEEDBACK SYSTEM; HUMAN; IN VITRO STUDY; NEUROPATHOLOGY; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SENILE PLAQUE;

MUS MUSCULUS;

EID: 1842504323     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.012     Document Type: Review

References (95)

1. SELKOE, D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
2. MARKESBERY, W.R. 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biol. Med. 23: 134-147.
3. ATWOOD, C.S. et al. 1999. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Metal Ions Biol. Syst. 36: 309-364.
4. CUMMINGS, J.L. et al. 1998. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51S: S2-S17.
5. GLENNER, G.G. & C.W. WONG. 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120: 885-890.
6. MASTERS, C.L. et al. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82: 4245-4249.
7. KANG, J. et al. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736.
8. ROBAKIS, N.K. et al. 1987. Chromosome 21q21 sublocalisation of gene encoding β-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome [letter]. Lancet 1: 384-385.
9. TANZI, R.E. et al. 1987. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235: 880-884.
10. TANZI, R.E. et al. 1988. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 331: 528-530.
11. VIGO-PELFREY, C. et al. 1993. Characterization of β-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61: 1965-1968.
12. PRELLI, F. et al. 1988. Different processing of Alzheimer's β-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochem. Biophys. Res. Commun. 151: 1150-1155.
13. PIKE, C.J. et al. 1991. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563: 311-314.
14. LORENZO, A. & B.A. YANKNER. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91: 12243-12247.
15. TANZI, R.E. & L. BERTRAM. 2001. New frontiers in Alzheimer's disease genetics. Neuron 32: 181-184.
16. SHERRINGTON, R. et al. 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760.
17. LEVY-LAHAD, E. et al. 1995. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973-977.
18. CHARTIER-HARLIN, M.C. et al. 1991. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353: 844-846.
19. MURRELL, J. et al. 1991. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254: 97-99.
20. SAUNDERS, A.M. et al. 1993. Association of apolipoprotein E allele epsilon4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
21. BLACKER, D. et al. 1998. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 19: 357-360.
22. REBECK, G.W. et al. 1995. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density lipoprotein receptor-related protein. Ann. Neurol. 37: 211-217.
23. Du, Y. et al. 1997. α2-Macroglobulin as Aβ-amyloid peptide-binding plasma protein. J. Neurochem. 69: 299-305.
24. NICOLL, J.A. et al. 2000. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47: 365-368.
25. SAMPIETRO, M. et al. 2001. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol. Aging 22: 563-568.
26. BERTRAM, L. et al. 2000. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290: 2302-2303.
27. FARRIS, W. et al. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA 100: 4162-4167.
28. QIU, W.Q. et al. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273: 32730-32738.
29. HILBICH, C. et al. 1991. Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease. J. Mol. Biol. 218: 149-163.
30. JARRETT, J.T., E.P. BERGER & P.T. LANSBURY, JR. 1993. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697.
31. SUZUKI, A. et al. 1994. High expression on Kunitz-type protease inhibitor-containing substances in the cerebral vessels of patients with Down syndrome. Tohoku J. Exp. Med. 174: 181-187.
32. TELLER, J.K. et al. 1996. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome [see comments]. Nat. Med. 2: 93-95.
33. CITRON, M. et al. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice [see comments]. Nat. Med. 3: 67-72.
34. XIA, W. et al. 1997. Enhanced production and oligomerization of the 42-residue amyloid β-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272: 7977-7982.
35. SHOJI, M. et al. 1992. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258: 126-129.
36. NAKAMURA, T. et al. 1994. Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann. Neurol. 36: 903-911.
37. MOTTER, R. et al. 1995. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38: 643-648.
38. HSIAO, K.K. et al. 1995. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15: 1203-1218.
39. HSIAO, K. et al. 1996, Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
40. WISNIEWSKI, K.E., H.M. WISNIEWSKI & G.Y. WEN. 1985. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17: 278-282.
41. BUSH, A.I. et al. 1994. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 265: 1464-1467.
42. HUANG, X. et al. 1997. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 272: 26464-26470.
43. ATWOOD, C.S. et al. 1998. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273: 12817-12826.
44. ATWOOD, C.S. et al. 2000. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75: 1219-1233.
45. MOIR, R. D. et al. 1999. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry 38: 4595-4603.
46. LOVELL, M.A. et al. 1998. Copper, iron, and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158: 47-52.
47. HALLIWELL, B. & J.M.C. GUTTERIDGE. 1984. Oxygen toxicity, oxygen radicals, transition metals, and disease. Biochem. J. 219: 1-14.
48. HARTTER, D.E. & A. BARNEA. 1988. Brain tissue accumulates 67copper by two ligand-dependent saturable processes: a high affinity, low capacity and a low affinity, high capacity process. J. Biol. Chem. 263: 799-805.
49. BASUN, H. et al. 1991. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J. Neural Transm. Parkinson's Dis. Dement. Sect. 3: 231-258.
50. CONNOR, J.R. et al. 1993. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci. Lett. 159: 88-90.
51. LOEFFLER, D.A. et al. 1994. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease, but not Parkinson's disease. Alzheimer Dis. Assoc. Disord. 8: 190-197.
52. ROBINSON, S.R. et al. 1995. Most amyloid plaques contain ferritin-rich cells. Alzheimer's Res. 1: 191-196.
53. CONNOR, J.R. et al. 1995. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65: 717-724.
54. PINERO, D.J., J. HU & J.R. CONNOR. 2000. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell. Mol. Biol. (Noisy-Le-Grand) 46: 761-776.
55. SMITH, M.A. et al. 1997. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94: 9866-9868.
56. SMITH, M.A. et al. 1998. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70: 2212-2215.
57. CHERNY, R.A. et al. 1999. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol. Chem. 274: 23223-23228.
58. CEBALLOS-PICOT, I. et al. 1996. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type - place of the extracellular glutathione peroxidase. Free Radical Biol. Med. 20: 579-587.
59. HENSLEY, K. et al. 1995. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65: 2146-2156.
60. MECOCCI, P., U. MACGARVEY & M.F. BEAL. 1994. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36: 747-751.
61. SAYRE, L.M. et al. 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68: 2092-2097.
62. SMITH, M.A. et al. 1994. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 91: 5710-5714.
63. SMITH, M.A. et al. 1997. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17: 2653-2657.
64. SMITH, C.D. et al. 1991. Excess brain protein oxidation and enzyme dysfunction in normal again and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 88: 10540-10543.
65. PAPPOLLA, M.A. et al. 1992. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am. J. Pathol. 140: 621-628.
66. FURUTA, A. et al. 1995. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am. J. Pathol. 146: 357-367.
67. GRUNDKE-IQBAL, I. et al. 1990. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. (Berlin) 81: 105-110.
68. SMITH, M.A. et al. 1994. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145: 42-47.
69. LOVELL, M.A. et al. 1995. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45: 1594-1601.
70. BUTTERFIELD, D.A. et al. 1994. β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200: 710-715.
71. BEHL, C. et al. 1994. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77: 817-827.
72. THOMAS, T. et al. 1996. β-Amyloid-mediated vasoactivity and vascular endothelial damage [see comments]. Nature 380: 168-171.
73. BRUCE, A.J., B. MALFROY & M. BAUDRY. 1996. β-Amyloid toxicity in organotypic hippocampal cultures: protection by Euk-8, a synthetic catalytic free radical scavenger. Proc. Natl. Acad. Sci. USA 93: 2312-2316.
74. TOMIYAMA, T. et al. 1996. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin: its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 271: 6839-6844.
75. YATIN, S.M., S. VARADARAJAN & D.A. BUTTERFIELD. 2000. Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42) - induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimer's Dis. 2: 123-131.
76. HARRIS, M.E. et al. 1995. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131: 193-202.
77. HUANG, X. et al. 1999. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616.
78. HUANG, X. et al. 1999. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274: 37111-37116.
79. LAMBERT, M.P. et al. 1998, Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95: 6448-6453.
80. WALSH, D.M. et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
81. KAYED, R. et al. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
82. DIKALOV, S.I. et al. 1999. Amyloid β peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides. J. Biol. Chem. 274: 9392-9399.
83. CUAJUNGCO, M.P. et al. 2000. Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc. J. Biol. Chem. 275: 19439-19442.
84. WHITE, A.R. et al. 2001. Homocysteine potentiates copper-and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J. Neurochem. 76: 1509-1520.
85. OPAZO, C. et al 2002. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277: 40302-40308.
86. SANO, M. et al. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336: 1216-1222.
87. PAPPERT, E.J. et al. 1996. α-Tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology 47: 1037-1042.
88. CRAPPER MCLACHLAN, D.R. et al. 1991. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1308.
89. ROGERS, J.T. et al. 2002. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277: 45518-45528.
90. ROGERS, J.T. et al. 2002. Alzheimer's disease drug discovery targeted to the APP mRNA 5′ untranslated region. J. Mol. Neurosci. 19: 77-82.
91. PORTER, J.B. & E.R. HUEHNS. 1989. The toxic effects of desferrioxamine. Bailliere's Clin. Haematol. 2: 459-474.
92. MULTHAUP, G. et al. 1996. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 271: 1406-1409.
93. CHERNY, R.A. et al. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676.
94. REGLAND, B. et al. 2001. Treatment of Alzheimer's disease with clioquinol. Dement. Geriatr. Cognit. Disord. 12: 408-414.
95. RITCHlE, C.W. et al. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial. Arch. Neurol. 60: 1685-1691.